0 projects

PES-HORISONT-EU-PES Horisont Europa

LTX-109. Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

Airborne viruses can be quite dangerous, especially for groups of risk (e.g. immunocompromised patients), as they can replicate and migrate from the upper (nose/nasopharynx) into lower respiratory tract (lungs) and lead to severe conditions such as pneumonia. Indeed, the nose is the main site for...

Awarded: NOK 0.30 mill.

Project Period: 2023-2023

Location: Troms - Romsa - Tromssa

PES2020-Prosj.etabl.støtte H2020

Development of the first of its kind medication for combined treatment of viral and bacterial conjunctivitis.

Pharma Holdings (https://www.pharmaholdings.no) is developing eyedrops for the treatment of conjunctivitis caused by both bacteria and viruses based on LTX-109. LTX-109 is a novel antimicrobial synthetic peptide with a fast-acting membrane lysing mode of action. It is a short cationic synthetic p...

Awarded: NOK 99,999

Project Period: 2020-2021

Location: Troms - Romsa - Tromssa